ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Zynerba Pharmaceuticals, Inc.

80 West Lancaster Avenue
Suite 300
Devon, PA 19333
United States
484-581-7505
http://www.zynerba.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees22

Key Executives

NameTitlePayExercisedYear Born
Mr. Armando Anido M.B.A., MBAChairman & CEO901.21kN/A1958
Ms. Terri B. SebreePres681.77kN/A1958
Mr. James E. FickenscherCFO & VP of Corp. Devel.260.09kN/A1964
Mr. William C. RobertsVP of Investor Relations & Corp. CommunicationsN/AN/A1969
Ms. Suzanne M. HanlonSec., VP of HR & Gen. CounselN/AN/A1957
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.

Corporate Governance

Zynerba Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2018 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.